title: Anemia management and the delay of chronic renal failure progression.
abstract: Interstitial fibrosis plays a key role in the progression of chronic kidney diseases. Analysis of the biologic effects of erythropoietin and of the pathophysiology of interstitial fibrosis suggest that treatment with epoetin may slow the progression of chronic kidney disease, both by decreasing interstitial fibrosis and by protecting against its consequences. The results of two small prospective studies and of a retrospective one also suggest that treatment with epoetin may have such protective effects.
authors.affiliation: University of Paris VI, Tenon Hospital (AP-HP) and INSERM U489, Paris, France. jerome.rossert@tnn.ap-hop-paris.fr
authors.forename: Jerome
authors.initials: J
authors.lastname: Rossert
authors.forename: Bruno
authors.initials: B
authors.lastname: Fouqueray
authors.forename: Jean Jacques
authors.initials: JJ
authors.lastname: Boffa
mesh_terms: D000740:Anemia / Q000150:complications* / Q000188:drug therapy*; D018450:Disease Progression; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D004921:Erythropoietin / Q000627:therapeutic use*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007676:Kidney Failure, Chronic / Q000517:prevention & control*; D007677:Kidney Function Tests; D008297:Male; D016032:Randomized Controlled Trials as Topic; D018570:Risk Assessment; D012720:Severity of Illness Index; D016896:Treatment Outcome
chemical_list: D004921:Erythropoietin